Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
10.20
-1.66 (-14.00%)
At close: Aug 1, 2025, 4:00 PM
10.60
+0.40 (3.92%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,619,167
Market Cap
6.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Aug 31, 2021 | 5 | 2 | 66.67% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARTL News
- 1 day ago - Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression - GlobeNewsWire
- 24 days ago - Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium - GlobeNewsWire
- 25 days ago - Artelo Biosciences Analyst See It As An Emerging Biotech - Benzinga
- 26 days ago - Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - GlobeNewsWire
- 5 weeks ago - Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing - GlobeNewsWire
- 7 weeks ago - Artelo Biosciences Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - GlobeNewsWire